📣From lead to pre-candidate nomination in 18 months. Explore the STORM Therapeutics case study

Contact
  • Integrated Drug Discovery

    Integrated Drug Discovery

    Overview

    We deliver truly integrated drug discovery programs. Our co-located teams accelerate compounds from target ID to candidate.

  • Target Identification & Validation

    Target Identification & Validation

    It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.

  • Hit Identification

    Hit Identification

    Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.

  • Hit-to-Lead

    Hit-to-Lead

    High-quality hits with early proof of concept are de-risked and profiled, ready to accelerate your program towards lead optimization.

  • Lead Optimization

    Lead Optimization

    Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.

Featured Resources

  • Modalities

    Modalities

    Overview

    Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.

  • Small Molecules

    Small Molecules

    Expert small molecule discovery from target ID to scale-up, delivering candidates designed for success and market impact.

  • Peptides

    Peptides

    Transforming complex peptide concepts into next-generation therapies through integrated design, advanced analytics, and collaborative end-to-end discovery expertise.

  • Targeted protein degradation

    Targeted protein degradation

    Leveraging induced proximity and CHARMED technology to rapidly design, test, and optimize degraders for previously ‘undruggable’ targets.

  • ADCs

    ADCs

    Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.

  • Biologics

    Biologics

    Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.

Featured Resources

  • Therapeutic Areas

    Therapeutic Areas

    Overview

    Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

  • Oncology and Immuno-Oncology

    Oncology and Immuno-Oncology

    Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.

  • Inflammation and Immunology

    Inflammation and Immunology

    Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.

  • Neuroscience

    Neuroscience

    Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.

  • Metabolic Diseases

    Metabolic Diseases

    Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.

Featured Resources

  • CellCentric Lead Optimisation Campaign - CCS1477

    CellCentric Lead Optimisation Campaign - CCS1477

    Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.

    Case study
  • About Sygnature

    About Sygnature

    At Sygnature Discovery, we deliver world-leading drug discovery solutions to accelerate your compound from idea to clinic.

  • Meet our Team

    Meet our Team

    Our leadership team brings diverse experience and insight, driving collaboration and innovation across drug discovery.

  • Careers

    Careers

    Explore careers at Sygnature Discovery and join a global team committed to science, collaboration, and integrity.

Event

23 April, 2026

London, UK

AngloNordic Life Science Conference

AngloNordic Life Science Conference

April 23, 2026 | London, UK

The AngloNordic Life Science Conference takes place on April 23 at County Hall in London. The meeting brings together life science companies and investors from the United Kingdom, the Nordic region, and wider Europe. The program includes company presentations, investment pitches, panel discussions, and one to one partnering. The format is designed for early stage biomedical and technology companies seeking investment and collaboration opportunities.

Meet the Sygnature Team at AngloNordic Life Science Conference 2026

At Anglonordic 2026, we are meeting with company leaders and investors to discuss how integrated discovery data can be used to prioritize programs, manage scientific risk, and support clear funding and progression decisions. Our conversations focus on practical collaboration models across chemistry, biology, and DMPK, and on how disciplined, evidence‑based workflows help move drug discovery programs toward preclinical candidate selection in challenging funding environments.

If you would like to arrange a meeting with Nick Ayers or Daniel O’Flynn, we are happy to schedule a time during the conference.

Book a Meeting

Nick Ayers – Vice-President Business Development – Europe

Daniel O’Flynn – Business Development Associate

Can’t attend AngloNordic Life Science Conference?
Connect with our team directly

Related Solutions

We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.

laboratory team collaborating on integrated drug discovery programs supporting end-to-end drug discovery from target ID to candidate selection.

Integrated Drug Discovery

Delivering co-located, multidisciplinary drug discovery programs that combine speed, precision, and scientific rigor to advance candidates with confidence.

Learn more
Therapeutic Areas

Therapeutic Areas

Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.

Learn more
DMPK

DMPK

Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.

Learn more
Chemistry

Chemistry

Global chemistry expertise and tailored strategies combining medicinal, synthetic, and process capabilities advancing candidate-quality molecules with transparent collaboration.

Learn more
Bioscientist

Bioscience

Tailored bioscience solutions combining advanced technologies and collaborative expertise to design robust assays and accelerate confident drug discovery decisions.

Learn more